$3M Gene Therapy—With a Catch - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

$3M Gene Therapy—With a Catch

Medicaid is testing a pay-for-performance deal that makes drugmakers refund millions if new sickle cell gene therapies fail.

  • By

  • Phil Galewitz

  • January 21, 2026

  • 8 min

Share

Clinical Scorecard: $3M Gene Therapy—With a Catch

At a Glance

CategoryDetail
ConditionSickle Cell Disease
Key MechanismsGene therapy reprograms stem cells to produce healthy red blood cells.
Target PopulationPrimarily Black Americans with sickle cell disease, approximately 100,000 individuals.
Care SettingSpecialized hospitals offering gene therapy.

Key Highlights

  • Gene therapies approved for patients 12 years and older.
  • Cost of therapies ranges from $2.2 million to $3.1 million per patient.
  • New payment model holds drug manufacturers accountable for treatment success.
  • Medicaid covers about half of Americans with sickle cell disease.
  • Potential to avoid hospitalizations and improve quality of life.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of sickle cell disease through blood tests.

Management

  • Gene therapy as a potential cure for eligible patients.

Monitoring & Follow-up

  • Federal evaluation to track patient outcomes and treatment effectiveness.

Risks

  • Limited number of hospitals offering therapy and potential complications from treatment.

Patient & Prescribing Data

Medicaid enrollees with sickle cell disease.

Gene therapy offers a chance to live without pain and complications.

Clinical Best Practices

  • Monitor patient outcomes to ensure treatment efficacy.
  • Consider fertility preservation options for patients undergoing chemotherapy.

Related Resources & Content

Original Source(s)

$3M Gene Therapy—With a Catch

  • by Phil Galewitz

  • January 21, 2026

Related Content

Low IMA Ligation Did Not Significantly Reduce Leaks

A randomized trial found similar short-term morbidity and 12-month functional outcomes with both approaches, while highlighting the need to balance perfusion with a tension-free anastomosis.

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.

Benchmark for Functional Vision Loss Uncovered in Older Adults

A nationally representative US cohort identified a contrast sensitivity threshold associated with self-reported visual disability.